© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
July 26, 2022
Closing out the program, Robert Zeiser, MD, shares what he is looking forward to in the field of graft-vs-host-disease.
Adverse events related to chronic graft-vs-host-disease therapies and strategies to manage these adverse effects are considered.
Robert Zeiser, MD, touches on additional therapeutic options for steroid-refractory chronic graft-vs-host-disease, such as extracorporeal photopheresis, mycophenolate, everolimus, and more.
Therapies for steroid-refractory chronic graft-vs-host disease, ibrutinib, ruxolitinib, and belumosudil, are explored in a comprehensive analysis.
A GVHD expert comments on the frontline therapy available for the condition.
Selection of prophylaxis regimen is reviewed followed by a discussion of the typical patient presentation of GVHD.